Program
tegtociclib
Also written as “PF-07220060 + PF-07104091 combination dose escalation”, “PF-07104091 + PF-07220060 + fulvestrant dose expansion” and “PF-07104091 + PF-07220060 + letrozole dose expansion”.
In Pfizer's pipeline, CDK2 inhibitor
. Its studies are mostly in Breast Neoplasms · Small Cell Lung Carcinoma, led by Pfizer.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 42 open or running | phase 2since Aug 21, 2020 | Aug 21, 2020 | Dec 31, 2026phase 2 · NCT04553133 |
- Named in Pfizer’s own pipeline as
tegtociclib PF-07104091
, phase 1, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 21, 2020First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT04553133 · 157 enrolled · United States, Argentina, Bulgaria and more
- Feb 21, 2022Phase 2 study in Breast NeoplasmsNCT05262400 · 235 enrolled · United States, Argentina, Brazil and more
- Jun 9, 2022Phase 1 study in HealthyNCT05431153 · 30 enrolled · United States
- Jul 1, 2025Phase 1 study in Healthy AdultsNCT07127770 · 9 enrolled · Netherlands
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT04553133
- Feb 26, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05262400
TargetBeta
“CDK2 inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, tegtociclib selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tum…”NCIt, read by Claude
“An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), ”NCIt, by rule
Other programs on CDK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| CDK2 Inhibitor INCB123667rule | Incyte | phase 3 | 7 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| CDK2 Inhibitor AVZO-021rule | avenzo-therapeutics-inc | phase 2 | 2 |
| CDK2 Inhibitor ECI830 | Novartis | phase 2 | 1 |
| CDK2 Degrader BG-75098rule | BeOne Medicines | phase 1 | 1 |
| CG-7321rule | chengdu-cynogen-bio-pharmaceutical-tech-co-ltd | phase 1 | 1 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
| ZE94-0605rule | eilean-therapeutics | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07127770Healthy Adults · Netherlands | 1 | Completed | Oct 8, 2025 | 9 |
| NCT05431153Healthy · United States | 1 | Completed | Oct 17, 2022 | 30 |
| NCT05262400Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Active, not recruiting | Feb 26, 2027 | 235 |
| NCT04553133Small Cell Lung Carcinoma · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | Dec 31, 2026 | 157 |
How it is read
Names in the registry
- “PF-07220060 + PF-07104091 combination dose escalation”, 8 entries
- “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
- “PF-07104091 + PF-07220060 + letrozole dose expansion”, 1 entry
- “PF-07104091 monotherapy dose escalation”, 1 entry
- “PF-07104091 + palbociclib + fulvestrant”, 1 entry
Codes read as this program: PF07104091.
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.